Abstract

Any person with progressive cognitive impairment should be studied with brain imaging to rule out a reversible cause, such as a benign brain tumor, a subdural hematoma, or hydrocephalus. Additionally, imaging can help separate the various types of currently not-treatable dementia and facilitate the prognosis of these disorders. Medial temporal atrophy on magnetic resonance imaging, and decreased metabolism in parietotemporal association cortex and retrosplenial region on positron emission tomography are early findings in Alzheimer's disease (AD). Amyloid deposition in AD and Lewy-body dementia help differentiate these disorders from dementias without amyloid deposition, such as frontotemporal dementia and corticobasal degeneration.

Original languageEnglish (US)
Title of host publicationEncyclopedia of Human Behavior
Subtitle of host publicationSecond Edition
PublisherElsevier Inc.
Pages707-717
Number of pages11
ISBN (Electronic)9780123750006
ISBN (Print)9780080961804
DOIs
StatePublished - Jan 1 2012

Keywords

  • Alzheimer's disease
  • Amyloid
  • Atrophy
  • Brain metabolism
  • Dementia
  • Diffuse Lewy-body disease
  • Frontotemporal dementia
  • Imaging
  • Magnetic resonance imaging (MRI)
  • Neuroimaging
  • Positron emission tomography (PET)
  • Single-photon emission computed tomography (SPECT)

ASJC Scopus subject areas

  • Psychology(all)

Fingerprint Dive into the research topics of 'Neuroimaging of Dementia'. Together they form a unique fingerprint.

Cite this